Literature DB >> 29247340

Assessing the opportunity costs of patients with multidrug-resistant organisms in hospitals.

Claudia Hübner1, Walter Ried2, Steffen Flessa3.   

Abstract

OBJECTIVES: The concept of opportunity cost can be applied to the utilization of hospital beds with special focus on patients colonized or infected with multidrug-resistant organisms. Blocked beds due to isolation measures or increased length of stay may result in opportunity costs if newly arriving patients have to be rejected and the hospital is confronted with revenue foregone. However, the amount of these costs is unclear, since different approaches are used in the literature to determine the respective costs. Our paper develops a concept to assess opportunity costs from the perspective of a hospital.
METHODS: The analysis is two-stage. In a first step, the probability of rejecting a patient due to over-occupancy in a hospital is calculated with a queuing model and a Monte Carlo simulation taking various assumptions into account. In a second step, the amount of the opportunity costs is calculated as an expected value applying a stochastic approach based on a potential patient pool.
RESULTS: Opportunity costs will occur only with a probability that is influenced, among others, by current bed occupancy rates. They have to be measured by average net revenue foregone, i.e., by the difference between average revenue foregone and average costs avoided.
CONCLUSIONS: Previous studies have a tendency of overestimating the occurrence or the size of opportunity costs with regard to the use of hospital beds. Nonetheless, its influence on the hospital budget is crucial and should be determined exactly.

Entities:  

Keywords:  Decision-making; Hospital; Monte Carlo simulation; Multidrug-resistant organisms; Net revenue foregone; Opportunity costs

Mesh:

Year:  2017        PMID: 29247340     DOI: 10.1007/s10198-017-0949-8

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  16 in total

Review 1.  Economic Notes: opportunity cost.

Authors:  S Palmer; J Raftery
Journal:  BMJ       Date:  1999-06-05

Review 2.  Transmission rates, screening methods and costs of MRSA--a systematic literature review related to the prevalence in Germany.

Authors:  A Tübbicke; C Hübner; A Kramer; N-O Hübner; S Fleßa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-10       Impact factor: 3.267

3.  Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment.

Authors:  M H Wernitz; S Keck; S Swidsinski; S Schulz; S K Veit
Journal:  Clin Microbiol Infect       Date:  2005-06       Impact factor: 8.067

4.  [Cost analysis concerning MRSA-infection in ICU].

Authors:  G Geldner; M Ruoff; H J Hoffmann; P Kiefer; M Georgieff; H Wiedeck
Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther       Date:  1999-07       Impact factor: 0.698

5.  Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.

Authors:  Marlieke E A de Kraker; Peter G Davey; Hajo Grundmann
Journal:  PLoS Med       Date:  2011-10-11       Impact factor: 11.069

6.  Opportunity costs and local health service spending decisions: a qualitative study from Wales.

Authors:  Sarah Karlsberg Schaffer; Jon Sussex; Dyfrig Hughes; Nancy Devlin
Journal:  BMC Health Serv Res       Date:  2016-03-25       Impact factor: 2.655

7.  Economic burden of multidrug-resistant bacteria in nursing homes in Germany: a cost analysis based on empirical data.

Authors:  Claudia Huebner; Marcus Roggelin; Steffen Flessa
Journal:  BMJ Open       Date:  2016-02-23       Impact factor: 2.692

8.  What is a hospital bed day worth? A contingent valuation study of hospital Chief Executive Officers.

Authors:  Katie Page; Adrain G Barnett; Nicholas Graves
Journal:  BMC Health Serv Res       Date:  2017-02-14       Impact factor: 2.655

9.  Vancomycin-resistant enterococci outbreak, Germany, and calculation of outbreak start.

Authors:  Ulrich Sagel; Berit Schulte; Peter Heeg; Stefan Borgmann
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

10.  Economics and preventing hospital-acquired infection.

Authors:  Nicholas Graves
Journal:  Emerg Infect Dis       Date:  2004-04       Impact factor: 6.883

View more
  1 in total

1.  In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital.

Authors:  Sabine Engler-Hüsch; Thomas Heister; Nico T Mutters; Jan Wolff; Klaus Kaier
Journal:  BMC Health Serv Res       Date:  2018-09-26       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.